EDIT vs JD · rev $32.3M vs P/E 7.6, rev $187.20B
Editas Medicine Inc (EDIT) versus JD.com Inc Adr (JD) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
JD.com Inc Adr (JD) is a internet retail company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported JD revenue for 2025-12-31 was $187.20B. Net income was $3.31B. Revenue was up 17.9% from 2024-12-31 to 2025-12-31. JD currently screens at market cap $45.56B and trailing P/E 7.6.
EDIT currently screens at market cap $375.2M. JD currently screens at market cap $45.56B and trailing P/E 7.6.
Not investment advice. Open the EDIT and JD stock pages for the full models.
Not investment advice.